



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

08.11.2023

Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome Of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Wednesday, 8th November, 2023**, at the office of company, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter and half year ended on 30th September, 2023.

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter and half year ended on ended 30th September, 2023.
2. Limited Review Report for the quarter and half year ended on ended 30th September, 2023.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:50 P.M.

The above information will be available on the website of the Company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking You,

For Titan Biotech Limited

Charanjit Singh
Company Secretary & Compliance Officer
M. No A12726



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended September 30, 2023 and the year to date results for the period 1st April 2023 to 30 September 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Report" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil
Mittal

Digitally signed
by Akhil Mittal
Date: 2023.11.08
15:11:35 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 08.11.2023

Place: New Delhi

UDIN: **23517856BGUXHS2277**



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended September 30, 2023 and the consolidated year to date results for the period from 1 April 2023 to 30 September 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Report" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

-
4. The Statement includes results of the Holding Company -Titan Biotech Limited and Associate Company - Peptech Biosciences Limited.
 5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its associates which have been approved and furnished to us by the management. Our Conclusion on the statement is not modified in respect of the above matter.
 6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
 7. The unaudited consolidated financial results also includes the Group's share of net profit after tax of Rs.49.23 lacs and total comprehensive income of Rs.49.23 Lacs for the Quarter ended 30th September 2023, as considered in the consolidated unaudited financial results, in respect of its Associates, based on their interim financial results of M/s Peptech biosciences Limited which have been reviewed by our Audit Firm. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of its associates, are based solely on such unaudited interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.
Our conclusion is not modified in respect of this matter.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil
Mittal

Digitally signed
by Akhil Mittal
Date: 2023.11.08
15:09:36 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 08.11.2023

Place: New Delhi

UDIN: **23517856BGUXHR9606**

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2023

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	INCOME						
	Revenue from operations	4,342.71	3,474.74	4,183.38	7,817.45	7,683.00	14,399.93
	Other Income	55.21	28.19	85.64	83.40	117.28	194.33
	Total Income	4,397.92	3,502.93	4,269.02	7,900.85	7,800.28	14,594.26
2	EXPENSES						
	Cost of Materials Consumed	2,044.78	1,891.56	2,178.59	3,936.34	3,962.98	7,080.54
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	77.42	(434.96)	(44.93)	(357.54)	(105.66)	(93.21)
	Employee Benefit Expenses	546.57	541.77	452.21	1,088.34	832.16	1,820.90
	Finance Costs	27.99	28.56	17.03	56.55	34.62	74.59
	Depreciation and Amortization Expenses	85.98	79.60	63.76	165.58	124.21	260.03
	Other Expenses	802.58	687.63	549.38	1,490.21	1,138.75	2,639.80
	Total Expenses	3,585.32	2,794.16	3,216.04	6,379.48	5,987.06	11,782.65
3	Profit/(loss) before exceptional items and tax (1-2)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
4	Exceptional Items						
5	Profit/ (loss) before tax (3+4)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
6	Tax expense						
	(I) Current Tax	209.90	167.40	268.61	377.30	450.47	721.44
	(II) Deferred Tax	2.38	0.74	(2.41)	3.12	(1.76)	(8.89)
	(III) Earlier year taxes	(2.59)	(0.31)	(3.43)	(2.90)	(3.43)	(3.43)
	Total Tax (I+II)	209.69	167.83	262.77	377.52	445.28	709.12
7	Profit (Loss) for the period after Tax (5-6)	602.91	540.94	790.21	1,143.85	1,367.94	2,102.49
8	Other comprehensive income (Net of Tax)						
	Items that will not be reclassified to profit or loss						
A.	(i) Re-measurement gain on defined benefit plans	2.08	2.08	-	4.16	-	8.31
	(ii) Income tax relating to these items	(0.52)	(0.53)	-	(1.05)	-	(2.09)
B	Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(i) Income tax relating to these items	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	1.56	1.55	-	3.11	-	6.22
9	Total Comprehensive Income for the period (7+8)	604.47	542.49	790.21	1,146.96	1,367.94	2,108.71
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
11	Other Equity						
12	Earnings per equity share (face value of Rs 10/- each) not annualised						9,782.79
	(1) Basic	7.30	6.55	9.56	13.84	16.55	25.44
	(2) Diluted	7.30	6.55	9.56	13.84	16.55	25.44

Notes:

- The above unaudited standalone financial results for the quarter and six months ended on 30.09.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 08, 2023. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and six months ended on 30th Sept. 2023, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place Delhi
Dated 08.11.2023

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2023

(Rs. IN LAKHS) except for EPS


Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,397.92	3,502.93	4,269.02	7,900.85	7,800.28	14,594.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	602.91	540.94	790.21	1,143.85	1,367.94	2,102.49
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	604.47	542.49	790.21	1,146.96	1,367.94	2,108.71
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	9,782.79
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	7.30	6.55	9.56	13.84	16.55	25.44
	(b) Diluted	7.30	6.55	9.56	13.84	16.55	25.44

NOTES :

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter and six months ended on 30.09.2023 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter and six months ended on 30.09.2023 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com. The statutory auditors of the company have carried out a limited review of the aforesaid results.
- The above unaudited standalone financial results for the quarter and six months ended on 30.09.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 08, 2023. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015. The results for the quarter and six months ended on 30th Sept. 2023, are available on the BSE Limited website (www.bseindia.com) and on the company's Website (www.titanbiotechltd.com).
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30.09.2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED


NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 08.11.2023


TITAN BIOTECH LIMITED
Standalone Balance Sheet as at 30th September, 2023

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2023 Unaudited	31/03/2023 Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	3,435.73	2,620.57
b. Capital Work-in-Progress	945.34	1,329.40
c. Right of use Assets	954.20	960.39
d. Intangible assets	7.16	8.52
e. Financial Assets		
(i) Investments	1,226.98	1,158.62
(ii) Other Financial Assets	176.98	161.52
Total Non-current assets	6,746.39	6,239.02
2. Current Assets		
a. Inventories	4,233.47	3,616.96
b. Financial Assets		
(i) Trade receivables	2,384.49	2,100.77
(ii) Cash and cash equivalents	456.38	486.37
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	452.15	626.46
Total Current assets	7,526.49	6,830.56
TOTAL ASSETS	14,272.88	13,069.58
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	10,781.01	9,782.79
TOTAL EQUITY	11,607.38	10,609.16
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	117.97	29.90
(ii) Lease liabilities	110.38	113.22
b. Deferred tax liabilities (Net)	124.91	120.74
c. Provisions	174.61	161.50
Total Non-Current Liabilities	527.87	425.36
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	606.25	669.96
(ii) Lease liabilities	21.88	38.10
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	-	-
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	486.55	554.97
(iv) Other financial liabilities	484.78	493.10
b. Other current liabilities	427.53	242.84
c. Provisions	33.20	33.21
d. Current Tax Liabilities (Net)	77.44	2.88
Total Current Liabilities	2,137.63	2,035.06
TOTAL EQUITY AND LIABILITIES	14,272.88	13,069.58

For Titan Biotech Limited


[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Date : 08.11.2023

TITAN BIOTECH LIMITED
Standalone Cash Flow Statement for the period ended on 30th September, 2023

(Rs. in Lakhs.)


Particulars	Six months ended	Six months ended
	30/09/2023	30/09/2022
	Unaudited	Unaudited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,521.37	1,813.22
Adjustment for :		
Finance Costs	56.55	34.62
Provisions	17.25	13.12
Earlier year Taxes	2.90	3.43
Depreciation and Amortization Expenses	165.58	124.21
Operating profit before working capital changes	1,763.65	1,988.60
Changes in working Capital:		
Inventories	(616.51)	(512.14)
Trade and other Receivables	(124.88)	(546.09)
Trade and other Payables	107.94	148.80
Cash generation from Operation	1,130.20	1,079.17
Payment of Direct Taxes	(302.74)	(374.74)
Net Cash generated/ (used) - Operating Activities	827.46	704.43
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Investment in shares	(68.35)	(275.63)
Purchase of Fixed Assets (incl.Capital WIP)	(595.32)	(464.77)
Right of use assets	6.19	19.70
Net Cash Generated/ (Used) - Investing Activities	(657.48)	(720.70)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	88.07	53.07
Repayment of Lease Liabilities	(19.05)	(14.48)
Proceeds/(Repayment) of Short-term Borrowings (Net)	(63.70)	(198.10)
Finance Cost paid	(56.55)	(34.62)
Dividend paid	(148.74)	(123.96)
Net Cash Generated/ (Used) - Financing Activities	(199.97)	(318.09)
Net Increase/ (Decrease) in Cash and Cash Equivalents	(29.99)	(334.36)
Add : Opening Cash and Cash Equivalents	486.37	681.39
Closing Cash and Cash Equivalents	456.38	347.03

Notes:

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited

Naresh Kumar Singla
[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Date : 08.11.2023

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2023

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	INCOME						
	Revenue from operations						
	Other Income	4,342.71	3,474.74	4,183.38	7,817.45	7,683.00	14,399.93
	Total Income	55.21	28.19	85.64	83.40	117.28	194.33
2	EXPENSES	4,397.92	3,502.93	4,269.02	7,900.85	7,800.28	14,594.26
	Cost of Materials Consumed	2,044.78	1,891.56	2,178.59	3,936.34	3,962.98	7,080.54
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	77.42	(434.96)	(44.93)	(357.54)	(105.66)	(93.21)
	Employee Benefit Expenses	546.57	541.77	452.21	1,088.34	832.16	1,820.90
	Finance Costs	27.99	28.56	17.03	56.55	34.62	74.59
	Depreciation and Amortization Expenses	85.98	79.60	63.76	165.58	124.21	260.03
	Other Expenses	802.58	687.63	549.38	1,490.21	1,138.75	2,639.80
	Total Expenses	3,585.32	2,794.16	3,216.04	6,379.48	5,987.06	11,782.65
3	Profit/(loss) before exceptional items and tax (1-2)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
4	Exceptional Items	-	-	-	-	-	-
5	Profit/ (loss) before tax (3+4)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
6	Tax expense:						
	(I) Current Tax	209.90	167.40	268.61	377.30	450.47	721.44
	(II) Earlier year taxes	2.38	0.74	(1.76)	3.12	(1.76)	(3.43)
	(III) Deferred Tax	(2.59)	(0.31)	(4.08)	(2.90)	(3.43)	(8.89)
	Total Tax (I+II)	209.69	167.83	262.77	377.52	445.28	709.12
7	Profit (Loss) for the period after Tax (5-6)	602.91	540.94	790.21	1,143.85	1,367.94	2,102.49
8	Share in Profit of Associate	49.23	75.12	122.48	124.35	295.20	381.93
9	Profit (Loss) for the period (7+8)	652.14	616.06	912.69	1,268.20	1,663.14	2,484.42
10	Other comprehensive income (Net of Tax)						
	Items that will not be reclassified to profit or loss						
A	(i) Re-measurement gain on defined benefit plans	2.08	2.08	-	4.16	-	8.31
	(ii) Income tax relating to these items	(0.52)	(0.53)	-	(1.05)	-	(2.09)
B	Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(i) Income tax relating to these items	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	1.56	1.55	-	3.11	-	6.22
11	Total Comprehensive Income for the period (7+8)	653.70	617.61	912.69	1,271.31	1,663.14	2,490.64
12	Net profit attributable to:						
	Owners of the holding company						
	Non-controlling interest						
13	Other comprehensive income attributable to :						
	Owners of the holding company						
	Non-controlling interest						
14	Total Comprehensive Income attributable to (10+11)						
	Owners of the holding company						
	Non-controlling interest						
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
16	Other Equity						
17	Earnings per equity share (face value of Rs. 10/- each) not annualised						
	(1) Basic	7.89	7.47	11.04	15.35	20.13	30.06
	(2) Diluted	7.89	7.47	11.04	15.35	20.13	30.06

Notes:

- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 08, 2023. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and six months ended Sept. 30, 2023, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter and six months ended on 30.09.2023 include the results of following:-
Associate Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended Sept. 30, 2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 08.11.2023

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2023

(Rs. IN LAKHS) except for EPS


S.NO.	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,397.92	3,502.93	4,269.02	7,900.85	7,800.28	14,594.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	812.60	708.77	1,052.98	1,521.37	1,813.22	2,811.61
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	652.14	616.06	912.69	1,143.85	1,367.94	2,484.42
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	653.70	617.61	912.69	1,271.31	1,663.14	2,490.64
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	10,164.72
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	7.89	7.47	11.04	15.35	20.13	30.06
	(b) Diluted	7.89	7.47	11.04	15.35	20.13	30.06

NOTES :

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter and six months ended on 30.09.2023 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and six months ended on 30th Sept 2023 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 08, 2023. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30.09.2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

Naresh Kumar Singla
NARESH KUMAR SINGLA
Managing Director
DIN-00027448




Place : Delhi
Dated :08.11.2023


TITAN BIOTECH LIMITED
Consolidated Balance Sheet as at 30th September, 2023

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2023	31/03/2023
	Unaudited	Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	3,435.73	2,620.57
b. Capital Work-in-Progress	945.34	1,329.40
c. Right of use Assets	954.20	960.39
d. Intangible assets	7.16	8.52
e. Financial Assets		
(i) Investments	1,733.26	1,540.55
(ii) Other Financial Assets	176.98	161.52
Total Non-current assets	7,252.67	6,620.95
2. Current Assets		
a. Inventories	4,233.47	3,616.96
b. Financial Assets	-	-
(i) Trade receivables	2,384.49	2,100.77
(ii) Cash and cash equivalents	456.38	486.37
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	452.15	626.45
Total Current assets	7,526.49	6,830.55
TOTAL ASSETS	14,779.16	13,451.50
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	11,287.29	10,164.70
TOTAL EQUITY	12,113.66	10,991.07
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	117.97	29.90
(ii) Lease liabilities	110.38	113.22
b. Deferred tax liabilities (Net)	124.91	120.74
c. Provisions	174.61	161.51
Total Non-Current Liabilities	527.87	425.37
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	606.25	669.96
(ii) Lease liabilities	21.88	38.10
(iii) Trade payables	-	-
(a) Total outstanding dues of micro enterprise and small enterprises	-	-
(b) Total outstanding dues of creditors other than micro enterprises and	486.55	554.97
(iv) Other Financial Liabilities	484.78	493.10
b. Other current liabilities	427.53	242.84
c. Provisions	33.20	33.21
d. Current Tax Liabilities (Net)	77.44	2.88
Total Current Liabilities	2,137.63	2,035.06
TOTAL EQUITY AND LIABILITIES	14,779.16	13,451.50

For Titan Biotech Limited


 [Naresh Kumar Singla]
 Managing Director
 DIN-00027448



Place : Delhi
Date : 08.11.2023

TITAN BIOTECH LIMITED
Consolidated Cash Flow Statement for the period ended on 30th September, 2023

(Rs. in Lakhs.)

Particulars	Six months ended	Six months ended
	30/09/2023 Unaudited	30/09/2022 Unaudited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,521.37	1,813.22
Adjustment for :	-	
Finance Costs	56.55	34.62
Earlier year Taxes	2.90	3.43
Provision for employees Benefits	17.25	13.12
Depreciation and Amortization Expenses	165.58	124.21
Operating profit before working capital changes	1,763.65	1,988.60
Changes in working Capital:		
Inventories	(616.51)	(512.14)
Trade and other Receivables	(124.88)	(546.09)
Trade and other Payables	107.94	148.80
Cash generation from Operation	1,130.20	1,079.17
Payment of Direct Taxes	(302.74)	(374.74)
Net Cash generated/ (used) - Operating Activities	827.46	704.43
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Investment in shares	(68.35)	(275.63)
Purchase of Property, Plant and Equipment (incl.Capital WIP)	(595.32)	(464.77)
Right of use assets	6.19	19.70
Net Cash Generated/ (Used) - Investing Activities	(657.48)	(720.70)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	88.07	53.07
Repayment of Lease Liabilities	(19.05)	(14.48)
Proceeds/(Rapyment)of Short-term Borrowings(Net)	(63.70)	(198.10)
Finance Cost paid	(56.55)	(34.62)
Dividend paid	(148.74)	(123.96)
Net Cash Generated/ (Used) - Financing Activities	(199.97)	(318.09)
Net Increase/ (Decrease) in Cash and Cash Equivalents	(29.99)	(334.36)
Add : Opening Cash and Cash Equivalents	486.37	681.39
Closing Cash and Cash Equivalents	456.38	347.03


Notes:

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited

Naresh Kumar Singla

[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Date : 08.11.2023